Lundbeck results disappoint, management in transition

Shares of H. Lundbeck A/S, which makes drugs for treating disorders of the central nervous system, closed down 7.3% on 8 November despite the release of favourable results for the third quarter and improved guidance for the year. A concern is the company’s transition to new management. 

Full text available to subscribers only. Click here for information on subscribing to MedNous.